Hint mode is switched on Switch off

Explore the most comprehensive database

1 000 000

bonds

100 000

stocks

175 910

ETF & Funds

100 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 1M bonds, 100K stocks, 100K indices, 17K ETF and 150K Mutual Funds
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Neogen: Disclosure Regarding Shareholder Approval Of The Neogen Corporation Amended And Restated Omnibus Incentive Plan. Except As Described Below, This Amendment Does Not Amend, Modify Or Update The Original Form 8k Or The Disclosures Therein, And Does Not Reflect Events Occurring After The Filing Of The Original Form 8k, Financial Statements And Exhibits

October 1, 2026 U.S. Securities and Exchange Commission
Show full article
This functionality is available for registred users only
Issuer — Neogen
  • Full name
    Neogen Corporation
  • Registration country
    USA
  • Industry
    Pharmaceutical Preparation and Biotechnology
  • М/S&P/F
    *** / *** / ***

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Other Company's News

Registration is required to get access.